This article, written by Dr. Peter Hotez, president of Sabin Vaccine Institute and dean of the National School of Tropical Medicine at Baylor College of Medicine, originally appeared in TAMEST (The Academy of Medicine, Engineering and Science of Texas) e-news.

Great news in the world of global health! A recent clinical trial for an experimental malaria vaccine has yielded successful results in protecting a large number of children against malaria with minimal side effects.

Sabin Vaccine Institute President Dr. Peter Hotez is leading the research at Texas Children’s Hospital and Baylor College of Medicine to develop the first-ever vaccine for Chagas disease.

Dr. Peter Hotez, president of the Sabin Vaccine Institute, was honored last week with the prestigious Abraham Horwitz Award for Excellence in Inter-American Public Health.

A midweek review of vaccine research and advocacy efforts in the news:

ABC News posted a video Thursday entitled “Parasitic Worms,” which features Sabin Vaccine Institute’s Dr. David Diemert discussing Sabin Vaccine Development work in Minas Gerais, Brazil. The video, which was produced in 2010 by Rockhopper, highlights the pervasiveness of hookworm infection among children in Brazil.

By Stephanie Bricking, Albert B. Sabin Archivist, University of Cincinnati

Remember the last time you had the flu? The exhaustion, the fever, the aching body?

In partnership with the Fraunhofer Center for Molecular Biotechnology and the Walter Reid Army Institute for Research, the Sabin Vaccine Institute has successfully expressed the hookworm-derived antigen Na-APR-1.

Dr. Peter Hotez, Sabin’s President, recently authored an op-ed in The Hinducalling on a new modern India to “invest in neglected tropical disease (NTD) elimination efforts--including the development of drugs, diagnostics, and vaccines--that will reduce the large NTD burden in South Asia.”

Pages